455 results on '"Fukuhara, Takasuke"'
Search Results
2. Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients
3. Virological characteristics of the SARS-CoV-2 Omicron XBB.1.5 variant
4. Virological characteristics of a SARS-CoV-2-related bat coronavirus, BANAL-20-236
5. Akaluc bioluminescence offers superior sensitivity to track in vivo dynamics of SARS-CoV-2 infection
6. Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5
7. saRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concern
8. Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant
9. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants
10. Rational in silico design identifies two mutations that restore UT28K SARS-CoV-2 monoclonal antibody activity against Omicron BA.1
11. Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine
12. Inhibitors of cannabinoid receptor 1 suppress the cellular entry of Lujo virus
13. Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing an anchored RBD: A randomized, observer-blind phase 1 study
14. Involvement of SARS‐CoV‐2 accessory proteins in immunopathogenesis
15. Virological characteristics of a SARS-CoV-2-related bat coronavirus, BANAL-20-236
16. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant
17. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation
18. A rapid and versatile reverse genetics approach for generating recombinant positive-strand RNA viruses that use IRES-mediated translation
19. Virological characteristics of the SARS-CoV-2 BA.2.86 variant
20. Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariant BA.5 after mRNA SARS-CoV-2 vaccination in kidney transplant recipients
21. The evolution of surgical treatment for gastrointestinal cancers
22. Neutralizing immunity against coronaviruses in Tanzanian health care workers.
23. Prolonged shedding of viable SARS‐CoV‐2 in immunocompromised patients with haematological malignancies: A prospective study.
24. Akaluc bioluminescence offers superior sensitivity to track in vivo dynamics of SARS-CoV-2 infection
25. NEDD4-binding protein 1 suppresses HBV replication by degrading pgRNA
26. Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine, in healthy individuals
27. Intelli-OVI: A new-generation clinical tool for monitoring emerging viral infections
28. Neutralizing antibody responses and cellular responses against severe acute respiratory syndrome coronavirus 2 omicron subvariant BA.5 after an mRNA severe acute respiratory syndrome coronavirus 2 vaccine dose in kidney transplant recipients
29. Characterization of SPP inhibitors suppressing propagation of HCV and protozoa
30. The development of a rapid, high-throughput neutralization assay using a SARS-CoV-2 reporter
31. Inhibitors of cannabinoid receptor 1 suppress the cellular entry of Lujo virus
32. A third dose of the BNT162b2 mRNA vaccine sufficiently improves the neutralizing activity against SARS-CoV-2 variants in liver transplant recipients
33. Evaluation of Broad Anti-Coronavirus Activity of Autophagy-Related Compounds Using Human Airway Organoids
34. Antiviral Activity of Micafungin and Its Derivatives against SARS-CoV-2 RNA Replication
35. Smoking enhances the expression of angiotensin-converting enzyme 2 involved in the efficiency of severe acute respiratory syndrome coronavirus 2 infection
36. Impact of Imprinted Immunity Induced by mRNA Vaccination in an Experimental Animal Model.
37. 新型コロナウイルスにおけるリバース・ジェネティクス法
38. Safety and Immunogenicity of SARS-CoV-2 Self-Amplifying RNA Vaccine Expressing Anchored RBD: A Randomised, Observer-Blind, Phase 1 Study
39. Roles of Lipoproteins and Apolipoproteins in Particle Formation of Hepatitis C Virus
40. Monitoring fusion kinetics of viral and target cell membranes in living cells using a SARS-CoV-2 spike-protein-mediated membrane fusion assay
41. Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing anchored RBD: a randomised, observer-blind, phase 1 study
42. Smoking enhances the expression of angiotensin‐converting enzyme 2 involved in the efficiency of severe acute respiratory syndrome coronavirus 2 infection
43. SARS-CoV-2 Omicron detection by antigen tests using saliva
44. Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant
45. Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5
46. Decreased roundabout 1 expression promotes development of intrahepatic cholangiocarcinoma
47. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion
48. Hepatitis C virus NS5A protein promotes the lysosomal degradation of diacylglycerol O-acyltransferase 1 (DGAT1) via endosomal microautophagy
49. Antiviral activity of ciclesonide acetal derivatives blocking SARS-CoV-2 RNA replication
50. Impact of JMJD6 on intrahepatic cholangiocarcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.